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BASIC SCIENCE
ELSEVIER
INTRATUMORAL NUCLEAR MORPHOLOGIC 
HETEROGENEITY IN PROSTATE CANCER
H. G. v a n  d e r  POEL, G. O. N. OOSTERHOF, H. E. SCHAAFSMA, F. M. J. DEBRUYNE,
a n d  J. A. SCHALKEN
ABSTRACT
Objectives. Tumor heterogeneity can be measured by quantifying variance of nuclear characteristics by 
image analysis. Heterogeneity of cell nuclear features correlated with increased local progression in prostate 
cancer. In the present study, the influence of tumor heterogeneity on prostate-specific antigen (PSA) recur­
rence after radical retropubic prostatectomy was analyzed and tumor heterogeneity was compared in pa­
tients with and without neoadjuvant hormonal therapy.
Methods. Retrospectively, radical prostatectomy material of 44 patients without and 12 patients with neoad­
juvant hormonal treatment with a postoperative follow-up of at least 4 years was studied. Each prostatectomy 
specimen was systematically embedded in paraffin, and each tumor area within the prostate was marked 
and analyzed by an image analysis system for 32 nuclear features comprising nuclear shape, size, DNA 
content, and chromatin pattern. Several clinical features were available: preoperative serum PSA, hemoglo­
bin concentration, Karnofsky score, tumor stage, and Gleason score.
Results. Increased tumor heterogeneity, as expressed by differences in karyometric values between tumor 
areas in nuclear shape and chromatin pattern within the tumor, was significantly correlated with earlier PSA 
recurrence rate. As compared with nonpretreated patients, hormonally pretreated specimens showed 
smaller and less heterogeneous tumors. In particular, chromatin pattern heterogeneity was decreased in 
patients who underwent preoperative hormonal treatment compared with patients who were not pretreated. 
However, decreased heterogeneity was accompanied by a higher percentage of aneuploid areas per tumor 
in the pretreated patients. Cox regression analysis showed that karyometric determination of nuclear shape 
heterogeneity in combination with preoperative PSA level could predict time to PSA recurrence after radical 
prostatectomy in patients without hormonal pretreatment.
Conclusions. Increase in karyometric tumor heterogeneity in nuclear shape and chromatin pattern was cor­
related with a shorter PSA recurrence-free interval after radical prostatectomy. Preoperative PSA and kary­
ometric tumor heterogeneity were the best predictors of PSA recurrence in a multivariate analysis. Intratu- 
moral heterogeneity was decreased in patients with prostate cancer who underwent neoadjuvant hormonal 
therapy. UROLOGY 49: 652-657, 1997. © 1997, Elsevier Science Inc. All rights reserved.
I mage analysis methods enable objective deter­
mination of nuclear and cellular features in light 
microscopy. Several studies showed the value of 
morphometric grading in prostate adenocarci­
noma.1-3 Nuclear shape1,2 correlated with prog­
nosis in patients with low-stage prostate carci-
F rom the Department o f  Urology, University Hospital, Nijme­
gen, and the Department o f  Pathology, Canisius-Wilhelmina 
Ziekenhuis, Nijmegen, The Netherlands 
Reprint requests: H. G. van der Poel, M.D., Ph.D., Department 
of Urology, University Hospital, PO Box 9101, 6500  HB Nij­
megen, The Netherlands 
Submitted: July 16, 1996, accepted (with revisions): October 
16, 1996
C o p y r ig h t  1 9 9 7  by E l se v ie r  Sc i e n c e  In c .
652 ALL RIGHTS RESERVED
noma. Other studies, however, could not confirm 
this correlation with prognosis.4
Tumor heterogeneity may have led to the incon­
sistent findings of morphometric analysis as a 
prognostic factor. Heterogeneity in ploidy pattern 
in the tumor was observed in 40% to 50% of 
cases.5,6 Nuclear shape and chromatin variation in 
the tumor were of higher predictive value than 
were absolute data obtained in radical prostatec­
tomy material.7
To reduce tumor size preoperatively, hormonal 
pretreatment has been suggested. Neoadjuvant 
hormonal treatment was shown to reduce the 
number of positive resection margins and lymph 
node métastasés 8,9 The influence on long-term
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TABLE I. Clinical stage and PSA recurrences*
Stage cTIa cTIb cTIc cT2a cT2b cT2c cT3a cT3b cT3c
Neoadjuvant
No 2(1) 7(2) 2(2) 12(1) 8(2) 5(1) 6 (2 ) 1(1) 1(1)
Yes 0 0 0 2(1) 0 2(1) 7(6) 1(1) 0
/n cases o f  neoadjuvant treatmentt clinical stage before hormonal manipulations were instituted is shown.
* Number of recurrences is shown in parentheses.
prognosis remains to be established. Hormonal 
treatment may change histomorphology of the tu­
mor. In the present study, tumor heterogeneity in 
nuclear morphology and ploidy pattern were eval­
uated to answer two questions: (1) Is morphologic 
intratumoral heterogeneity correlated with prog­
nosis? and (2) Does neoadjuvant treatment influ­
ence tumor heterogeneity?
MATERIAL AND METHODS
From  1986 to 1992, 56 consecutive radical prostatectomy 
specimens were obtained. Forty-four patients underwent sur­
gery w ithout prior horm onal intervention, whereas 12 pa­
tients were treated with horm onal agents before surgery.
Patient age ranged from 42 to 73 years (median 65). For 
each patient, preoperative clinical stage was available and was 
obtained by digital rectal examination (DRE), transrectal u l­
trasound (TRUS), and sextant prostate biopsies. Moreover, 
serum prostate-specific antigen (PSA), hemoglobin, and acid 
phosphatase levels and performance status were documented. 
Four- to 10-year follow-up data (median 5.1 years) were avail­
able. PSA recurrence was taken as the end point, and was 
performed by the Hybritech Tandem-E singlepomt assay; 
analysis after February 1, 1995 was perform ed with the m ul­
tipoint assay. All patients reached nadir of PSA value several 
m onths after surgery. PSA recurrence was defined as an in­
crease in serum PSA level of more than 1 ng/mL and 0.04 ng/ 
mL for the singlepoint and m ultipoint Hybritech Tandem-E 
assay, respectively. Hormonal treatment consisted of maximal 
horm onal blockade with a luteinizing hormone-releasing hor­
mone (LHRH)-agonist (mostly goserelin) and an antiandro­
gen (flutamide) for at least 2 months. Radical prostatectomy 
was performed within 8 weeks after horm onal manipulation.
Material of radical prostatectomy was cut for evaluation of 
the entire prostate in quarter-prostate sections. Material was 
routinely processed by fixation in formaldehyde. For embed­
ding, paraffin was used. After embedding, 4 -^m  sections were 
cut. From each block (at least 10 per patient), a liematoxylin- 
eosin (HE) and adjacent Feulgen-stained slide was obtained. 
On the HE-stained slide, all tum or areas were marked by the 
pathologist. An experienced uropathologist reviewed all HE- 
stained slides and m arked each tum or area. Different tumor 
areas were discriminated based on Gleason grade, m orphol­
ogy, and individual location. W hen large tum or areas were 
present with clear variation in Gleason grade, those areas were 
separately m arked and analyzed. In 56 specimens, 349 differ­
ent tum or areas were detected. For each separate tumor lo­
cation, we estimated volume by delineating the tumor area 
and multiplying it by 4 ¡im (section thickness). Subsequent 
sections were analyzed, and data were sum m ed per tumor 
area. The m arked tum or areas were drawn on the adjacent 
Feulgen-stained slide, and each tumor area was analyzed by 
an image analysis system as described previously .10 At least 
50 nuclei per tum or area were selected random ly and analyzed 
for nuclear shape, size, DNA content, and chromatin pattern
(Markovian texture) features .10 The system automatically 
measured all nuclei present in the image. Overlapping nuclei 
were automatically rejected on the basis of abnormalities in  
shape. Because segm entation problem s could occur if debris 
or degenerated nuclei were p resen t in the image, a technician 
judged every segmented nucleus and  rejected incorrectly seg­
m ented and degenerated nuclei. Autologous leukocytes pres­
ent on the slide were selected for reference of 2 c for DNA 
ploidy analysis. Overall analysis of one tum or area required 
approximately 60 minutes.
W ithin  each tumor, the selected tum or areas were com ­
pared. For each tumor, we were able to calculate the highest 
and lowest value for each nuclear feature per tum or area. 
Therefore, we defined as a m easure for in tra tum oral hetero­
geneity the difference betw een the highest and  lowest value 
for nuclear shape, size, and  chrom atin  pattern. W hen  differ­
ences between tum or areas w ith in  a specim en were high, tu ­
mor heterogeneity was considered high, whereas hom ogene­
ity was defined when only slight differences in nuclear 
features am ong different tum or areas w ith in  one prostatec­
tomy specimen were detected. Moreover, ploidy analysis was 
performed for each tum or area. A neuploidy was defined when 
a peak in the DNA histogram  was present over 2.5 c, which 
means that no discrim ination was m ade between triploidy and 
tetraploidy. For each tum or, the percentage of aneuploid tu ­
mor foci was calculated.
The m orphom etric and clinical data were com pared with 
PSA recurrence by multivariate Cox regression analysis using 
SPSS/PC+ software. The forw ard-conditional m ethod was ap­
plied w ith a P value of 0.05 for entry and  of 0.10 for removal. 
To evaluate the influence of neoadjuvant horm onal treatment, 
we applied the nonparam etric  M ann-W hitney 17 test.
RESULTS
Distribution of clinical stage and grade is shown 
in Table I. Pathologic staging findings are shown 
in Table II.
The overall PSA recurrence rate was 39.3%. All 
patients developed pathologic proven recurrence, 
with increase in serum PSA values. Pathologic 
stage tended to correlate with PSA recurrence in 
patients both with and without neoadjuvant treat­
ment, but this was not statistically significant (Ta­
ble II).
In a multivariate analysis of clinical and kary- 
ometric features, heterogeneity in nuclear shape 
was the best predictor of pathologic tumor stage. 
The number of tumor foci per specimen was cor­
related with the total tumor volume (Pearson, r = 
0.69, P = 0.001). Karyometric tumor heteroge­
neity increased with the number of tumor foci and 
total tumor volume.
UROLOGY 49 (4), 1997 653
TABLE II. Pathologic stage and PSA recurrence *
Stage pT2a pT2b pT2c pT3a pT3b pT3c pT4a
Neoadjuvant
No 7 [0] 3(0) 13(3] 11 (5] 2 (1) 7(3) 1 (1)
Yes 5 (3)
* Number of recurrences in pci reni lies es.
0 2(2) 2(2) 0 3(3) 0
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FIGURE l.  Comparison of difference in L2 (chromatin 
pattern feature) vaiues within the tumor; that is, hetero­
geneity in chromatin pattern. The error bar shows the 
standard deviation (a). The mean range (maximai and 
minimal vaiue) pertum orofthe L2 feature is aiso shown 
(b). PSA recurrence: No (hatched columns): yes (open 
columns).
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FIGURE 2. Comparison of difference in PASS (nu­
clear shape) values within the tumor; that is, hetero­
geneity in nuclear shape. The error bar shows the 
standard deviation (a). The mean range (maximal and 
minimal value) per tumor of the PASS feature is also 
shown (b). PSA recurrence: No (hatched columns); yes 
(open columns).
Whereas clinical staging was not significantly
different between patients with and without hor- treated tumors. In particular, heterogeneity in 
monal pretreatment, pathologic stages were sig­
nificantly higher in patients with no previous 
treatment. Several nuclear features were differ-
chromatin pattern (Fig. 1) and nuclear shape 
(MPASS, Fig. 2) was lower in patients with 
neoadjuvant hormonal treatment. The maximal
ent between hormonally pretreated and nonpre- and minimal values per group are shown in Fig-
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ures lb  and 2b. The length of the bar corre­
sponds to the difference values as show n in Fig­
ures la  and 2a. The percentage of aneuploid 
tum or foci w ith in  the tum or was higher in the 
neoadjuvant group (Fig. 3).
In a univariate Cox regression analysis, several 
clinical features correlated w ith PSA recurrence in 
the group w ithout pretreatm ent (Table III). Of the 
nuclear features describing heterogeneity, that 
is, differences w ithin the tumor, heterogeneity 
in chrom atin pattern (DL2) and nuclear shape 
(DPASS) were negatively correlated w ith the PSA 
recurrence-free interval. In the neoadjuvantly 
treated patients, as for those w ithout pretreatment, 
the PSA recurrence-free interval also tended to de­
crease w ith  an increase in tum or heterogeneity, as 
assessed by karyometric analysis (Figs. 1, 2). Be­
cause only 12 patients were included in this group, 
no statistical analysis could be performed.
The multivariate Cox regression analysis for the 
prediction of PSA recurrence-free interval in the 
group w ithout pretreatm ent (n = 44) showed pre­
operative PSA level and heterogeneity in nuclear 
shape to be the best predictors (Table IV).
COMMENT
Prognosis after radical surgery for prostate can­
cer is dependent on pathologic grade and the 
status of the resection m argins.11 Local extension 
of disease decreases recurrence and progression- 
free intervals.
N uclear shape, quantita ted  by image analysis 
m ethods, was show n by some investigators to 
provide prognostic inform ation in addition to 
tum or stage in low-stage prostate carcinom a.1“3 
O thers, however, could no t confirm  the prog­
nostic value of nuclear shape and propagated 
variation of nuclear size w ith in  the tum or.4 A 
possible explanation for this discrepancy is that 
prostate cancers occur m ultifocally in m ost 
cases. A lthough little is know n about the way in 
w hich tum ors progress and becom e invasive or 
m etastasize, genetic instability  is assum ed to 
play an  im portan t role in  the process. Selecting 
only the m orphologically m ost atypic tum or area 
for grading may no t provide a reflection of the 
spectrum  of m alignant genetic changes that oc­
cur in the prostate.
For renal carcinoma, nuclear shape and chro­
matin changes within the tum or are highly corre­
lated w ith tum or progression in localized cancer.10 
In metastasized renal tumors, heterogeneity of the 
primary tum or was of no predictive value in prog­
nosis,10 putatively because in disseminated disease 
genetic instability has already resulted in a highly 
malignant advanced tum or cell line determining 
prognosis. This was confirmed by the finding that
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FIGURE 3. Comparison by PSA recurrence o f per­
centage o f aneuploid tumor cell foci within the tumor 
in pretreated patients and in patients not pretreated. 
Recurrence: No (hatched columns); yes (open col­
umns).
in advanced disease prognosis was correlated w ith 
the absolute values of aberrant nuclear shape and 
DNA content rather than  w ith  intratum oral het­
erogeneity.10
In  p rosta te  cancer, in tra tu m o ra l heterogeneity  
was detected for G leason g rad e ,12 DNA plo idy ,5,6 
p53 m u ta tio n s ,13 and and rogen  recep to r expres­
sion .14 H eterogeneity in  nuclear shape and ch ro ­
m atin  pattern  was show n to correlate  w ith local 
tum or progression.7 M oreover, the coefficient of 
variation in nuclear size, ra th e r than  the absolute 
m ean value, correlated w ith  survival after radical 
prostatectom y.4 In the p resen t study , nuclear 
features correlated w ith  PSA recu rrence  after 
radical prostatectom y. A bsolute m orphology  n u ­
clear values w ere less im p o rtan t for predicting  
progression than  was varia tion  in  nuclear char­
acteristics w ith in  the tum or. An increase in  n u ­
clear polym orphism  and  heterogeneity  in chro­
m atin  pattern  was inversely  corre la ted  w ith  the 
PSA recurrence-free in terval. W e assum e that ge­
netic instability  causes the  in tra tu m o r differ­
ences.
N eoadjuvant horm onal trea tm en t influenced 
tum or heterogeneity. C om parison  of m aterial af­
ter neoad juvan t trea tm en t w ith  m ateria l from 
patients treated  only w ith  surgery  show ed that 
the tum ors w ere m uch  sm aller and  less he te ro ­
geneous in the form er group. W ith  regard to 
neoadjuvant treatm ent, the p resen t study  was 
perform ed on  m aterial from  nonrandom ized  
studies. Clinical tum or stage in  the  neoad juvan t 
and non-neoad juvan t g roup , how ever, was com ­
parable, w hereas patho log ic  stage was signifi­
cantly lower in  the p a tien ts  treated  neoad ju ­
vantly, suggesting th a t th e  h o rm o n a l trea tm ent 
caused so-called “ dow ns tag ing .”9 A lthough only
UROLOGY 49 (4), 1997 655
TABLE III. Univariate Cox regression 
analysis of clinical, pathologic, and 
karyometric features for the prediction of the 
PSA recurrence-free interval in patients 
without neoadjuvant treatment (n = 44)
Parameter Beta P Value
Age 0.0592 0.1611
Karnofsky score 0.0362 0.4826
Preoperative PSA level 0.0415 0.0612
Clinical stage 0.0200 0.1887
Pathologic stage 0.3060 0.0777
Tumor size 0.1518 0.2477
Gleason score 0.1592 0.7363
Karyometry*
DPASS 0.2889 0.0275
DFPE 21.1 101 0.1880
DFELL 13.9092 0.0403
DPPR 0.0472 0.0205
DL2 5.5422 0.2896
DAREA 0.0092 0.6398
Mean FPE 2.6307 0.8914
Mean PASS 0.1 195 0.5928
Mean AREA 0.0259 0.4899
Mean PPR 0.0968 0.3398
Mean FELL 2.0199 0.8248
Key: FP£ =  nuclear roundness factor, FELL ~  fo rm  ellipse (major axis divided by 
minor axis); PASS  — nuclear shape feature based on smoothed Freeman difference 
chain code; AREA = nuclear size; DL2 = Markovian chromatin texture feature—  
entropy; PPR =  polyploidy rate; DPASS =  the diffcrcncc between the minimal and 
maximal M PASS  value o f  tumor areas within the tum or ,
D indicates difference beLween highest and lowest wi/ue between tumor ¿uecrs within 
one tumor .
* A selection was made of  the hiii^ometnc/eatures. All/enlures not presented con­
cerning nuclear si*e, shape, D N A  content, and ploidy pattern did not show corre­
lation with PSA recurrence rate.
TABLE IV. Multivariate Cox regression 
analysis of clinical, pathologic, and 
karyometric features for the prediction of the
PSA recurrence-free interval
Parameter Beta P Value
DPASS 0.3674 0.01 15
Preoperative PSA levei 0.0571 0.0171
Key; DPASS — the difference between the m inim al and  maxima! MPASS value o f  
tumor areas within the tu m o r
12 patients were included in the neoadjuvant 
group, patients with more heterogeneous tu­
mors, like the patients who were not pretreated, 
had a shorter PSA recurrence-free interval. The 
trend toward an increased percentage of aneu- 
ploid cell populations in patients treated neoad- 
juvantly, despite the decrease in tumor size and 
nuclear heterogeneity as compared with tumors 
not pretreated, needs further analysis. This find­
ing may partly explain the higher PSA recurrence
rate of the patients with hormonal pretreatmeni. 
Patient groups are too small to allow us to draw 
any conclusions regarding the long-term effects 
of neoadjuvant treatment on prognosis.
Nuclear appearance discloses information re­
garding tumor malignancy in prostate cancer. To 
obtain adequate information on prognosis, one 
should analyze different tumor areas to estimate 
intratumoral heterogeneity. Because nuclear mor- 
phometric analysis is a time-consuming proce­
dure, it cannot yet replace visual tumor grading. 
Neoadjuvant hormonal treatment appears to re­
duce intratumoral heterogeneity. In this small 
population, such reduction was not correlated 
with improved prognosis. The finding of increased 
aneuploidy in patients treated neoadjuvantly is 
also of interest.
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